Evidence map›Paper›PMID 38782299›Full record

SynthesisJournal of thrombosis and haemostasis : JTH2024

Genome-wide investigation of exogenous female hormones, genetic variation, and venous thromboembolism risk.

Emily K Hasser, Jennifer A Brody, Traci M Bartz, Florian Thibord, Ruifang Li-Gao, Anni Kauko, Kerri L Wiggins, Maris Teder-Laving, Jihye Kim, Gaëlle Munsch and 17 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of thrombosis and haemostasis : JTH, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Addressing the perimenopause: what's blood got to do with it?Research and practice in thrombosis and haemostasis · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Emily K HasserDepartment of Epidemiology, University of Washington, Seattle, WA, USA.
Jennifer A BrodyCardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA.
Traci M BartzDepartments of Biostatistics and Medicine, University of Washington, Seattle, WA, USA.
Florian ThibordINSERM, Bordeaux Population Health Research Center, UMR 1219, University of Bordeaux, Bordeaux, France; Laboratory of Excellence on Medical Genomics (GENMED), Evry, France.
Ruifang Li-GaoDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Anni KaukoDepartment of Internal Medicine, University of Turku, Turku, Finland.
Kerri L WigginsCardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA.
Maris Teder-LavingInstitute of Genomics, University of Tartu, Tartu, Estonia.
Jihye KimDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Gaëlle MunschINSERM, Bordeaux Population Health Research Center, UMR 1219, University of Bordeaux, Bordeaux, France.
Helen G HaileDepartment of Epidemiology, University of Washington, Seattle, WA, USA.
Jean-Francois DeleuzeCEA, Centre National de Recherche en Génomique Humaine (CNRGH), Université Paris-Saclay, Evry, France; Centre D'Etude du Polymorphisme Humain, Fondation Jean Dausset, Paris, France; Laboratory of Excellence on Medical Genomics (GENMED), Evry, France.
Astrid van Hylckama VliegDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Alisa S WolbergDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Anne BolandCEA, Centre National de Recherche en Génomique Humaine (CNRGH), Université Paris-Saclay, Evry, France; Laboratory of Excellence on Medical Genomics (GENMED), Evry, France.
Pierre-Emmanuel MorangeHematology Laboratory, La Timone University Hospital of Marseille, Marseille, France; Centre de recherche en CardioVasculaire et Nutrition, INSERM, INRAE, Aix-Marseille University, Marseille, France.
FinnGen, Estonia Biobank research teamEstonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.
Peter KraftDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Charles J LowensteinDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Joseph EmmerichDepartment of Vascular Medicine, Saint-Joseph Hospital Group, University of Paris Cité, Paris, France; UMR1153, INSERM Centre for Research in Epidemiology and Statistics (CRESS), Paris, France.
Colleen M SitlaniCardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA.
Pierre SuchonHematology Laboratory, La Timone University Hospital of Marseille, Marseille, France; Centre de recherche en CardioVasculaire et Nutrition, INSERM, INRAE, Aix-Marseille University, Marseille, France.
Frits R RosendaalDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Teemu NiiranenDepartment of Internal Medicine, University of Turku, Turku, Finland; Department of Internal Medicine, Division of Medicine, Turku University Hospital, Turku, Finland; Department of Public Health Solutions, Finish Institute of Health and Welfare, Helsinki, Finland.
Christopher KabrhelDepartment of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA; Department of Emergency Medicine, Harvard Medical School, Boston, MA, USA.
David-Alexandre TrégouëtINSERM, Bordeaux Population Health Research Center, UMR 1219, University of Bordeaux, Bordeaux, France; Laboratory of Excellence on Medical Genomics (GENMED), Evry, France.
Nicholas L SmithDepartment of Epidemiology, University of Washington, Seattle, WA, USA; Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA; Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Office of Research and Development, Seattle, WA, USA. Electronic address: nlsmith@u.washington.edu.

Funding

CHARGE Consortium: Omics Discovery for CVD and Aging PhenotypesR01HL105756 · NHLBI · UNIVERSITY OF WASHINGTON · PI Bruce M Psaty, NICHOLAS L SMITH · 2011 to 2026
$9.5M
Structural and Nucleotide Variation as Genomic Risks for Venous Thrombosis: TOPMED and INVENT CollaborationR01HL154385 · NHLBI · UNIVERSITY OF WASHINGTON · PI PANKRATZ, NATHAN D, SMITH, NICHOLAS L · 2020 to 2023
$3.0M
Genetic Discovery and Functional Validation to Identify Precursors of Clot Embolization in those with a Deep Vein ThrombosisR01HL147894 · NHLBI · UNIVERSITY OF WASHINGTON · PI SMITH, NICHOLAS L, WOLBERG, ALISA S. · 2021 to 2024
$2.6M
Model system of oral contraceptive-induced VTE: integrating genomic, transcriptomic, and proteomic discovery with functional biologyR33HL141791 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI LOWENSTEIN, CHARLES J, SMITH, NICHOLAS L · 2020 to 2022
$2.0M
Model system of oral contraceptive-induced VTE: integrating genomic, transcriptomic, and proteomic discovery with functional biologyR61HL141791 · NHLBI · UNIVERSITY OF ROCHESTER · PI LOWENSTEIN, CHARLES J, SMITH, NICHOLAS L · 2018 to 2019
$1.4M
NHLBI NIH HHS R01 HL105756NHLBI NIH HHS R01 HL147894NHLBI NIH HHS R01 HL154385NHLBI NIH HHS R33 HL141791NHLBI NIH HHS R61 HL141791
6 · The paper itself

Abstract

backgroundIncreased risk of venous thromboembolism (VTE) is a life-threatening side effect for users of oral contraceptives (OCs) or hormone therapy (HT).

objectivesTo investigate the potential for genetic predisposition to VTE in OC or HT users, we conducted a gene-by-environment case-only meta-analysis of genome-wide association studies (GWAS).

methodsUse or nonuse of OCs (7 studies) or HT (8 studies) at the time of the VTE event was determined by pharmacy records or self-report. A synergy index (SI) was modeled for each variant in each study and submultiplicative/supramultiplicative gene-by-environment interactions were estimated. The SI parameters were first meta-analyzed across OC and HT studies and subsequently meta-analyzed to obtain an overall estimate. The primary analysis was agnostic GWAS and interrogated all imputed genotypes using a P value threshold of <5.0 × 10

resultsThe VTE case-only OC meta-analysis included 2895 OC users and 6607 nonusers; the case-only HT meta-analysis included 2434 HT users and 12 793 nonusers. In primary GWAS meta-analyses, no variant reached genome-wide significance, but the smallest P value approached statistical significance: rs9386463 (P = 5.03 × 10

conclusionThe candidate variant approach to identify submultiplictive/supramultiplicative associations between genetic variation and OC and HT use identified a new association with common genetic variation in F11, while the agnostic interrogations did not yield new discoveries.

Indexed as

Genetic Predisposition to DiseaseGenome-Wide Association StudyVenous ThromboembolismContraceptives, Oral, HormonalEstrogen Replacement TherapyFemaleGene-Environment InteractionGenetic VariationHumansPolymorphism, Single NucleotideRisk AssessmentRisk FactorsContraceptives, Oral, Hormonalepidemiologygene-environment interactionhormone replacement therapyoral contraceptivesvenous thromboembolism

Identifiers

PMID38782299
PMCPMC12208689

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.